NCT00136409已完成2 期
A Phase II Study of Gleevec (Imatinib Mesylate) In Patients With BCR-Negative Myeloproliferative Disorders Including Patients With Idiopathic Myelofibrosis With Myeloid Dysplasia or Chronic Myelomonocytic Leukemia
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 2
- 主要终点
- To determine the overall response rate of Gleevec as a single agent in patients with BCR-negative myeloproliferative disorders including myelofibrosis with myeloid metaplasia and chronic myelomonocytic leukemia
研究概览
简要总结
The purpose of this study is to determine the effects (good and bad) of Gleevec in patients with BCR-negative myeloproliferative disorders including myelofibrosis with myeloid metaplasia and chronic myelomonocytic leukemia.
详细描述
Gleevec will be administered at a dose of 400 mg orally once daily.
Patients will continue to receive the drug until either drug progression or the development of intolerable side effects.
Patients will be assessed with a complete blood count weekly for the first 8 weeks and will have monthly physical examinations and bone marrow examinations every 3 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have a clinical diagnosis of myelofibrosis with myeloid metaplasia or chronic myelomonocytic leukemia (CMML). Patients may be entered based on a prior cytogenetic karyotype showing the absence of the Philadelphia chromosome.
- •Patients may be entered prior to completion of reverse transcription-polymerase chain reaction (RT-PCR) or fluorescent in situ hybridization (FISH) studies, but a patient who is subsequently found to be BCR-ABL or FISH positive will be removed from protocol treatment. FISH will only be performed on patients with a normal karyotype. A PCR sample will be sent on all patients.
- •The patients with myelodysplasia must have French-American-British (FAB) subtype chronic myelomonocytic leukemia (CMML) defined as peripheral blood monocytosis, and less than 30 percent blasts in the peripheral blood or the bone marrow.
- •The patients with myelofibrosis with myeloid metaplasia can have one of the following: agnogenic myeloid metaplasia (idiopathic myelofibrosis), or post-polycythemic myeloid metaplasia (post-polycythemic myelofibrosis), or post-thrombocythemic myeloid metaplasia.
- •Estimated life expectancy of 6 months or greater.
- •Serum bilirubin equal to or less than twice the upper limit of normal.
- •Serum SGOT and SGPT equal to or less than twice the upper limit of normal.
- •Serum creatinine equal to or less than twice the upper limit of normal.
- •Age at least 18 years.
- •Greater than 4 weeks from any chemotherapy (except hydroxyurea), radiotherapy, immunotherapy, or systemic glucocorticoid therapy (non-glucocorticoid hormonal therapy is allowed). Systemic glucocorticoid therapy for non-malignant disease is allowed.
- •The last dose of hydroxyurea must be 24 hours prior to the initiation of Gleevec.
- •Greater than 2 months following bone marrow or peripheral blood stem cell transplantation or treatment with donor lymphocyte infusion (DLI).
排除标准
- •Uncontrolled active infection.
- •Pregnancy or nursing mothers.
- •Patients with myelofibrosis with myeloid metaplasia or chronic myelomonocytic leukemia who have transformed to acute myelogenous leukemia.
- •Prior treatment or diagnosis of acute myelogenous leukemia.
- •Patients with Philadelphia positive cytogenetics by either peripheral blood or bone marrow sampling.
- •Eastern Cooperative Oncology Group (ECOG) performance status >
- •Prior exposure to Gleevec.
- •Active central nervous system (CNS) disease.
- •Evidence of infection with the human immunodeficiency virus.
- •Active psychiatric or mental illness making informed consent or careful clinical follow-up unlikely.
研究组 & 干预措施
Mono-Therapy Gleevec
Experimental
Gleevec administered orally at a pre-determined dose once daily.
干预措施: Imatinib mesylate (Drug)
结局指标
主要结局
To determine the overall response rate of Gleevec as a single agent in patients with BCR-negative myeloproliferative disorders including myelofibrosis with myeloid metaplasia and chronic myelomonocytic leukemia
时间窗: 3 years
次要结局
- to determine the biologic activity of Gleevec in patients with BCR-negative myeloproliferative disorders including myelofibrosis with myeloid metaplasia or chronic myelomonocytic leukemia(3 years)
- To determine the safety and efficacy of Gleevec as a single agent in patients with BCR-negative myeloproliferative disorders including myelofibrosis with myeloid metaplasia or chronic myelomonocytic leukemia(3 years)
研究者
Daniel J. DeAngelo, MD, PhD
Principal Investigator
Dana-Farber Cancer Institute
研究点 (2)
Loading locations...
相似试验
终止
2 期
Safety Study of Gleevec® in Children With Pulmonary HypertensionPulmonary HypertensionNCT00583115Indiana University1
已完成
2 期
CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)LeukemiaNCT00955916H. Lee Moffitt Cancer Center and Research Institute38
已完成
2 期
Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's LymphomaT Cell Non-Hodgkin LymphomaNCT00684411Dana-Farber Cancer Institute12
已完成
2 期
Gleevec Idiopathic Pulmonary Fibrosis (IPF) StudyLung DiseaseIdiopathic Pulmonary FibrosisPulmonary FibrosisNCT00131274Daniels, Craig E., M.D.120
已完成
2 期
Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine CancerRecurrent Uterine SarcomaUterine CarcinosarcomaNCT00075400National Cancer Institute (NCI)26